Under the collaboration, both companies will focus on the development of a therapeutic hypothermia core cooling technology to protect the brain during cardiac arrest and traumatic brain injury.

Dynasil president and chief executive officer Steven Ruggieri said the agreement establishes the intellectual property and commercialization framework through which Dynasil and Mayo Clinic will advance early-stage innovations to patented products for therapeutic applications.

"Dynasil uniquely complements Mayo Clinic’s initiatives with unsurpassed research, development and manufacturing expertise, coupled with a unique ability to assess and prioritize discoveries for commercialization," Ruggieri added.

Dynasil and Mayo Clinic are also working together on a blood storage technology designed to extend the shelf life of blood products.